Vesselon Acquires FDA-Approved lipid microsphere drug Imagent Vesselon, an oncology therapeutics company, today acquired an FDA-approved drug Imagent for diagnostic purposes as a contrast agent for...
FDA approves first Tenosynovial giant cell tumour treatment Turalio (Pexidartinib) The US FDA has given its approval to Turalio (pexidartinib) capsules for the treatment of symptomatic tenosynovial giant cell tumour (TGCT) associated with severe morbidity or functional limitations that surgery has failed to impr...
Find More
Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came afte...
Find More
CHMP opines positively for 13 Drugs for a variety of disease The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has endorsed the use of 13 medicinal drugs for a variety of indications. These include five new medications and eight existing ones whose use is extended ...
Find More
FDA Approves Eli Lilly's Baqsimi, the first treatment for Severe Hypoglycemia The U.S. FDA gave its approval to Baqsimi nasal powder, for the treatment of Severe Hypoglycaemia in patients with diabetes ages four and older. Baqsimi is a powder administered into the nose and is the first non-injectable emergency t...
Find More
Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s Lyrica The U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate the access of high-quality generic medicines at lower prices to patients. Lyrica is the second most selling drug of the...
Find More
PureHealth acquires LYT-100 to treat lymphedema PureTech Health, a pioneer in the development of therapies for dysfunctions in the brain-immune-gut axis, has announced to acquire a clinical-stage drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema. The candidat...
Find More
AI-powered drug-maker Recursion Pharmaceuticals secures USD 121 M to accelerate its clinical programs Recursion Pharmaceuticals, a next-gen biopharma company, has raised USD 121 Million in Series C financing. The Series C round was led by Baillie Gifford's flagship investment trust, Scottish Mortgage Investment...
Find More
Osivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the cl...
Find More
NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer...
Find More
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....
Find More
Neurofibromatosis is a progressive and autosomal dominant inherited disorder of the nervous system w.....
Find More
Hemophilia, a genetic bleeding disorder characterized by a clotting factor protein deficiency. Intak.....
Find More
Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It .....
Find More
T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....
Find More
An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
